Stock DRMA DERMATA THERAPEUTICS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Consensus Dermata Therapeutics, Inc.

Equities

DRMA

US2498453065

Delayed Nasdaq
Other stock markets
 19:21:26 29/04/2024 BST 		5-day change 1st Jan Change
0.3424 USD -0.09% Intraday chart for Dermata Therapeutics, Inc. -2.56% -43.87%
03-21 Dermata Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
01-05 Wall Street Set to Open Lower as Monthly Jobs Data Much Stronger Than Expected MT

Evolution of the average Target Price on Dermata Therapeutics, Inc.

Price target over the last 5 years

History of analyst recommendation changes

b16c18.BRen4DlIECK6wIQmOv2nswQ5IJ8Y8eO_HWY4lpigAFw.XE_V2FgQWxvOsLFSU86K8UpbSsAtvZSJUgtJzP7vSQZqdea0SSpha-OkzQ~ccc3c8950e596947b3575d0005f70738

Analyst Recommendations on Dermata Therapeutics, Inc.

Maxim Adjusts Price Target on Dermata Therapeutics to $4 From $16, Keeps Buy Rating MT
DERMATA THERAPEUTICS : Brookline Capital Starts Dermata Therapeutics at Buy with $14 Price Target MT
DERMATA THERAPEUTICS : Maxim Starts Dermata Therapeutics at Buy with $9 Price Target MT
More recommendations

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
1
Last Close Price
0.3427 USD
Average target price
1.5 USD
Spread / Average Target
+337.70%
High Price Target
1.5 USD
Spread / Highest target
+337.70%
Low Price Target
1.5 USD
Spread / Lowest Target
+337.70%

Consensus detail

Consensus revision (last 18 months)

Analysts covering Dermata Therapeutics, Inc.

Maxim
Brookline Capital Management

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar
  1. Stock Market
  2. Equities
  3. DRMA Stock
  4. Consensus Dermata Therapeutics, Inc.